Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer

Journal of the National Cancer Institute

Volumn 88, Issue 24, 1996, Pages 1828-1833

  Tormey, Douglass C ^a   Gray, Robert ^b   Falkson, Hendre C ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030479062     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.24.1828     Document Type: Article

References (12)

1. Tormey DC, Gray R, Abeloff MD, Roseman DL, Gilchrist KW, Barylak EJ, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1992;10:1848-56.
2. Falkson HC, Gray R, Wolberg WH, Gilchrist KW, Harris JE, Tormey DC, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study [published erratum appears in J Clin Oncol 1990;8:1600]. J Clin Oncol 1990;8:599-607.
3. Tormey DC, Jordan VC. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 1984;4:297-302.
4. Tormey DC, Rasmussen P, Jordan VC. Long-term adjuvant tamoxifen study: clinical update [letter]. Breast Cancer Res Treat 1987;9:157-8.
5. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974;27:365-75.
6. Tormey D, Fisher B, Bonadonna G, Carter S, Davis L, Glidewell O, et al. Proposed guidelines - report from the Combined Modality Trials Working Group in breast cancer. In: Carbone PP, Sears ME, editors. Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. Bethesda (MD): DHEW Publ No. (NIH)77-1192. 1977:20-35.
7. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact lest in rxc contingency tables. J Am Stat Assoc 1983;78:427-34.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50: 163-70.
10. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14: 2738-46.
11. Fisher B, Dignam J. Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients wth negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
12. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74:297-9.